RVMD
Revolution Medicines, Inc.
NasdaqGS Healthcare United States
207,68 $US
+0.50% today
+162.82% YTD · +345.86% 1Y
50
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
19
Hedge funds tracked
Latest available SEC 13F filings
63
/ 100
STRONG

Analysis Revolution Medicines, Inc. (RVMD) — Kairos Score 63/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Key info

👔
CEO
Dr. Mark A. Goldsmith M.D., Ph.D.
📍
HQ
700 Saginaw Drive, Redwood City, CA, 94063, United States
👥
Employees
883
💰
Market cap
44 444 800 000,00 $US
💸
Dividend yield
—

🕴️ Insider activity (90 days)

50 transactions — 0 buys and 79 sales reported by Revolution Medicines, Inc. executives.

SA
Sandler Alan B.
Chief Development Officer · 2026-09-29
Other
SA
Sandler Alan B.
Chief Development Officer · 2026-09-29
Sell
SA
Sandler Alan B.
Chief Development Officer · 2026-09-29
Sell

🏦 Hedge Funds

19 institutional funds report a position on RVMD in their latest SEC quarterly filing.

BlackRock, Inc.
FMR LLC
Jupiter Topco LLC
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC

📰 Recent news

15 recent articles on RVMD.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Revolution Medicines, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of RVMD on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 50 insider transactions over 90 days
✅ All 19 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year